SVB Leerink Initiates Coverage On Denali Therapeutics with Outperform Rating, Announces Price Target of $50
SVB Leerink analyst Marc Goodman initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Outperform rating and announces Price Target of $50.